Clinical Trial Update: a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD） [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability, and pharmacokinetic study of multiple subcutaneous injections of B1344 in patients with nonalcoholic fatty liver disease and nonal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• B1344 Injection (B1344)

Snippet

Sponsor: Tasly Biopharmaceuticals Co., Ltd. | Conditions: NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis) | Phase 1 | Status: RECRUITING